NASDAQ:BCPC - Balchem Stock Price, News & Analysis

$84.59
-2.52 (-2.89 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$84.19
Now: $84.59
$87.24
50-Day Range
$84.24
MA: $94.24
$103.66
52-Week Range
$73.16
Now: $84.59
$117.79
Volume107,543 shs
Average Volume116,896 shs
Market Capitalization$2.74 billion
P/E Ratio28.10
Dividend Yield0.53%
Beta1.12
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Read More…

Industry, Sector and Symbol

Industry Chemicals & allied products
Sub-IndustrySpecialty Chemicals
SectorBasic Materials
Current SymbolNASDAQ:BCPC
CUSIP05766520
CIK9326
Phone845-326-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$643.68 million
Cash Flow$4.2022 per share
Book Value$22.63 per share

Profitability

Net Income$78.57 million

Miscellaneous

Employees1,135
Market Cap$2.74 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive BCPC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCPC and its competitors with MarketBeat's FREE daily newsletter.


Balchem (NASDAQ:BCPC) Frequently Asked Questions

What is Balchem's stock symbol?

Balchem trades on the NASDAQ under the ticker symbol "BCPC."

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem announced an annual dividend on Wednesday, December 12th. Shareholders of record on Wednesday, December 26th will be paid a dividend of $0.47 per share on Friday, January 18th. This represents a yield of 0.59%. The ex-dividend date is Monday, December 24th. This is an increase from Balchem's previous annual dividend of $0.42. View Balchem's Dividend History.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) posted its quarterly earnings data on Thursday, August, 1st. The basic materials company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.08. The basic materials company earned $161.60 million during the quarter, compared to analyst estimates of $163.14 million. Balchem had a return on equity of 13.87% and a net margin of 12.27%. The firm's revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the business posted $0.76 EPS. View Balchem's Earnings History.

When is Balchem's next earnings date?

Balchem is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Balchem.

What price target have analysts set for BCPC?

4 brokers have issued 1-year price targets for Balchem's stock. Their forecasts range from $95.00 to $127.00. On average, they anticipate Balchem's share price to reach $107.3333 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price. View Analyst Price Targets for Balchem.

What is the consensus analysts' recommendation for Balchem?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Balchem.

What are Wall Street analysts saying about Balchem stock?

Here are some recent quotes from research analysts about Balchem stock:
  • 1. According to Zacks Investment Research, "Balchem Corporation provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. Balchem Company consists of four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications. " (8/5/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a comparable universe-derived EV-to-EBITDA multiple approach. EV-to-EBITDA multiple to our 2019 diluted EBITDA per share of $3.64, we derive a target of $110 per share. Risks include, but are not limited to: (1) slower-than-anticipated growth in Balchem’s base businesses; (2) a global fracking industry slowdown; (3) inability to launch new nutrition segment products; and (4) failure by Balchem’s partner Curemark to obtain approval for its autism drug candidate." (5/6/2019)

Has Balchem been receiving favorable news coverage?

Media stories about BCPC stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Balchem earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the basic materials company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Balchem.

Are investors shorting Balchem?

Balchem saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 815,200 shares, an increase of 15.7% from the June 30th total of 704,300 shares. Based on an average daily trading volume, of 109,500 shares, the short-interest ratio is currently 7.4 days. Currently, 2.6% of the company's shares are short sold. View Balchem's Current Options Chain.

Who are some of Balchem's key competitors?

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Opko Health (OPK), Innovative Industrial Properties (IIPR), Glacier Bancorp (GBCI), CVS Health (CVS), Alphabet (GOOG), Starbucks (SBUX), Texas Pacific Land Trust (TPL), Analog Devices (ADI), Endo International (ENDP) and NVIDIA (NVDA).

Who are Balchem's key executives?

Balchem's management team includes the folowing people:
  • Mr. Theodore L. Harris, Chairman and Chief Exec. Officer (Age 54)
  • Mr. William A. Backus CPA, Chief Accounting Officer (Age 53)
  • Mr. Mark A. Stach, Gen. Counsel & Corp. Sec.
  • Mr. David F. Ludwig, VP & Gen. Mang. of Industrial Products (Age 61)
  • Mr. Carl Martin Bengtsson, Chief Financial Officer

Who are Balchem's major shareholders?

Balchem's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.56%), BlackRock Inc. (14.56%), Brown Capital Management LLC (11.75%), Vanguard Group Inc. (11.21%), Wasatch Advisors Inc. (4.04%) and Conestoga Capital Advisors LLC (2.54%). Company insiders that own Balchem stock include Daniel E Knutson and Scott C Mason. View Institutional Ownership Trends for Balchem.

Which major investors are selling Balchem stock?

BCPC stock was sold by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Ellis Investment Partners LLC, Allianz Asset Management GmbH, Invesco Ltd., JPMorgan Chase & Co., Renaissance Technologies LLC, Atlanta Capital Management Co. L L C and Van ECK Associates Corp. View Insider Buying and Selling for Balchem.

Which major investors are buying Balchem stock?

BCPC stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Morgan Stanley, Wasatch Advisors Inc., BlackRock Inc., BlackRock Inc., Scout Investments Inc., Conestoga Capital Advisors LLC and Royal Bank of Canada. Company insiders that have bought Balchem stock in the last two years include Daniel E Knutson and Scott C Mason. View Insider Buying and Selling for Balchem.

How do I buy shares of Balchem?

Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Balchem's stock price today?

One share of BCPC stock can currently be purchased for approximately $84.59.

How big of a company is Balchem?

Balchem has a market capitalization of $2.74 billion and generates $643.68 million in revenue each year. The basic materials company earns $78.57 million in net income (profit) each year or $3.01 on an earnings per share basis. Balchem employs 1,135 workers across the globe.View Additional Information About Balchem.

What is Balchem's official website?

The official website for Balchem is http://www.balchem.com/.

How can I contact Balchem?

Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at 845-326-5600 or via email at [email protected]


MarketBeat Community Rating for Balchem (NASDAQ BCPC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Balchem and other stocks. Vote "Outperform" if you believe BCPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel